Sanofi Stock Forecast 2035: Bull, Bear, and Base Case

01. Historical Context

Sanofi in context: what kind of long-term stock this has been

A 2035 forecast should start from the facts investors can verify now: EUR 74.04 as of May 15, 2026, a 10-year range of EUR 44.62 to EUR 94.70, and a 10-year price CAGR of 4.1%. Those figures describe a company that has created value, but not through an endlessly expanding multiple.

The operating base entering this decade is stronger than the stock chart alone suggests. FY 2025 net sales were EUR 43.626 billion, up 9.9% at CER, and IFRS EPS was EUR 6.40. Q1 2026 net sales were EUR 10.509 billion, up 13.6% at constant exchange rates, while business EPS was EUR 1.88, up 14.0% at CER. That is enough to justify a long-term constructive view as long as the post-Dupixent bridge continues to form.

The discipline for 2035 is to avoid pretending precision where none exists. The right framework is a range tied to franchise durability, launch depth, pipeline throughput, and the valuation investors are still willing to pay for those cash flows in ten years' time.

2035 bull, bear, and base case for Sanofi — Long-term ranges anchored to the current price, 10-year trading history, and the latest verified company and institutional data.

Sanofi framework across investor time horizons

Horizon	What matters now	Current datapoint	What would strengthen the thesis
1-3 months	Execution versus guidance	Q1 2026 net sales were EUR 10.509 billion, up 13.6% at constant exchange rates, while business EPS was EUR 1.88, up 14.0% at CER.	Management keeps 2026 guidance and brand-level momentum remains intact.
6-18 months	Valuation versus revisions	MarketScreener showed Sanofi on about 12.9x trailing 2025 earnings, 10.9x 2026 estimated earnings, and 10.1x 2027 estimated earnings. Consensus EPS on MarketScreener was EUR 6.852 for 2026 and EUR 7.372 for 2027, implying about 7.6% growth into 2027.	Consensus EPS moves higher while the multiple does not need to do all the work.
To 2035	Structural compounding	10-year price range EUR 44.62 to EUR 94.70; 10-year CAGR 4.1%.	The company sustains growth through launches, pipeline conversion, and disciplined capital allocation.

02. Key Forces

Five forces that will shape the path to 2035

First, Sanofi needs durable growth beyond one franchise. The stock's long-term quality will be defined by whether 2026-2030 launches become established profit pools by the early 2030s.

Second, the company needs R&D productivity. Sanofi's AI and digital investments are relevant here because they target the speed and hit rate of drug development, not just corporate storytelling.

Third, capital allocation matters over a decade. Buybacks, bolt-on M&A, and the monetization or strategic use of the Opella stake can all change the compounding math.

Fourth, the macro and rate regime still matters. IMF growth is not recessionary, but a structurally higher-rate world would cap the size of the rerating available to defensive equities.

Fifth, the starting multiple is helpful. A stock priced near 11x forward earnings has a better long-term cushion than one starting above 20x.

Current factor scorecard for Sanofi

Factor	Current Assessment	Bias	Why it matters now
Starting valuation	About 10.9x 2026 EPS	Bullish	A low starting multiple gives the 2035 thesis room.
Launch replacement	Q1 2026 launch sales already EUR 1.2 billion	Bullish	A decade is enough time for launches to become core franchises.
AI and R&D efficiency	AI target generation and faster launch timing already cited by management	Bullish	Higher R&D productivity matters more in 2035 than in 2027.
Franchise concentration	Dupixent still dominant in 2026	Neutral	The long horizon gives time to diversify, but the need is real.
Sector valuation backdrop	Healthcare still discounted relative to the S&P 500 per J.P. Morgan	Neutral to Bullish	Multiple normalization can help if fundamentals keep improving.

03. Countercase

What would break the long-term case

A long-dated bear case for Sanofi is mostly an execution risk. If the company cannot build enough follow-on franchises, the market will continue to treat it as a mature cash-flow vehicle rather than a growth platform.

Another risk is that healthcare policy keeps compressing the sector's relative multiple. J.P. Morgan's note says public healthcare multiples are already at 30-year lows relative to the S&P 500, which means sentiment is cheap but also vulnerable to staying cheap.

A third risk is that AI becomes a productivity promise with weaker real-world returns than management hopes. The IMF specifically listed disappointment over AI productivity as one downside macro risk in April 2026.

A fourth risk is that sector breadth remains weak. FactSet still had Health Care among the weakest earnings sectors in Q1 2026, which is a reminder that valuation support alone does not fix earnings revisions.

2035 risk map

Risk	Latest datapoint	Current assessment	Bias
Failure to diversify	Still a live issue in 2026	Most important long-term risk	Bearish
Policy and sector discount	Healthcare still cheap relative to the S&P 500	Could persist	Neutral
AI productivity gap	IMF flagged disappointment over AI productivity as a downside risk	Unresolved	Neutral
Revision weakness	FactSet still sees healthcare as a weak breadth sector	Shorter-term pressure can bleed into long-term sentiment	Neutral

04. Institutional Lens

How institutional inputs help frame the decade view

Long-term work should use institutional inputs only where they actually help. The IMF gives the macro corridor, FactSet gives the valuation and earnings-breadth backdrop, and J.P. Morgan gives a useful read on where healthcare sits relative to the broader equity market.

Those sources do not tell you where Sanofi trades in 2035, but they do tell you something important: the stock is starting from a discounted relative valuation, in a sector where the bar is high and where stock-specific execution can matter a lot.

Company-specific sell-side data reinforce that view. MarketScreener listed 24 analysts on May 7, 2026 with an Outperform consensus, average target EUR 97.10, low target EUR 82.00, and high target EUR 112.00. For a 2035 framework, that says today's market still leans conservative on the longer runway.

Named institutional inputs used in this article

Source	Latest update	What it says	Why it matters here
MarketScreener, May 7, 2026	MarketScreener listed 24 analysts on May 7, 2026 with an Outperform consensus, average target EUR 97.10, low target EUR 82.00, and high target EUR 112.00.	Analysts still see upside because the stock is screening at a low-teens trailing P/E and about 11x forward earnings.	That institutional setup matters because Sanofi does not need an aggressive multiple to outperform if launches keep delivering.
IMF, April 2026	Global growth 3.1% in 2026 and 3.2% in 2027.	The IMF said downside risks still dominate because of conflict, fragmentation, and disappointment over AI productivity.	A slower macro tape usually limits multiple expansion for defensive growth names as well as cyclical names.
FactSet, May 1, 2026	Health Care was one of only two S&P 500 sectors reporting a year-over-year earnings decline; the S&P 500 forward P/E was 20.9x.	FactSet's message is that broad equity valuations are not cheap even as healthcare revisions remain mixed.	That raises the bar for stock-specific execution and makes relative valuation important.
J.P. Morgan Asset Management, 2026	Public healthcare multiples sit at 30-year lows relative to the S&P 500 despite USD 318 billion of M&A across 2,500-plus transactions in 2025.	J.P. Morgan's sector view is that policy noise has compressed healthcare valuations relative to the market.	That helps explain why solid pharma execution can still re-rate if policy fears fade.

05. Scenarios

Bull, base, and bear paths with explicit review dates

A 2035 map should reward compounding, not fantasy. The base case assumes Sanofi compounds earnings and dividends from a low starting multiple, but never becomes a premium-growth darling.

The practical review dates are not annual price targets alone. Investors should review whether the post-Dupixent revenue mix is visibly broader by 2028, whether the company keeps translating launch momentum into durable franchises by 2030, and whether valuation is still justified by the 2031-2035 earnings base.

2035 scenario map for Sanofi

Scenario	Probability	Target range	Trigger	When to review
Bull case	20%	EUR 150 to EUR 190	Sanofi builds multiple new blockbusters, keeps R&D productivity high, and the market rewards a broader growth profile with a better-than-historical multiple.	Review at each annual report and major pipeline reset.
Base case	55%	EUR 105 to EUR 135	EPS compounds steadily from the 2026-2027 base and the multiple stays around low-teens.	Review every 12 months and after major patent-cycle updates.
Bear case	25%	EUR 80 to EUR 100	Dupixent concentration lasts too long and the company remains a slow-growth cash generator rather than a broader platform.	Review if launches stop scaling or consensus EPS turns flat.